Ataxin-1 Polyclonal Antibody

The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. The function of the ataxins is not known. This locus has been mapped to chromosome 6, and it has been determined that the diseased allele contains 40-83 CAG repeats, compared to 6-39 in the normal allele, and is associated with spinocerebellar ataxia type 1 (SCA1). At least two transcript variants encoding the same protein have been found for ATXN1.

The Ataxin-1 Polyclonal Antibody is a highly specific and reliable tool designed for the detection and analysis of Ataxin-1 protein expression in various biological samples. This antibody has been meticulously developed using advanced immunization techniques, ensuring its exceptional sensitivity and specificity.

Ataxin-1 is a protein that plays a crucial role in the regulation of neuronal function and development. Dysregulation or mutations in the Ataxin-1 gene have been associated with the development of neurodegenerative disorders, including spinocerebellar ataxia type 1 (SCA1). Therefore, the accurate detection and quantification of Ataxin-1 protein expression are of paramount importance in understanding the underlying mechanisms of these diseases.

The Ataxin-1 Polyclonal Antibody exhibits outstanding performance in various applications, including Western blotting, immunohistochemistry, and immunofluorescence. It has been extensively validated for its specificity, ensuring minimal cross-reactivity with other proteins, thus providing reliable and reproducible results.

This antibody is produced using high-quality materials and undergoes rigorous quality control procedures to ensure batch-to-batch consistency and optimal performance. It is supplied as a ready-to-use solution, eliminating the need for time-consuming and error-prone antibody preparation.

With its exceptional sensitivity and specificity, the Ataxin-1 Polyclonal Antibody is an indispensable tool for researchers and clinicians involved in the study of neurodegenerative disorders. Its reliable performance and ease of use make it an ideal choice for a wide range of applications, facilitating accurate and insightful investigations into the role of Ataxin-1 in disease pathogenesis.